Home LiteratureArticle Details
PMID: 1712624 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.

British journal of cancer ·Vol. 63 ·No. 6 ·1991-06-00 ·Pages 967-70

Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CH, Neal DE

Abstract

Expression of the p53, the epidermal growth factor receptor (EGFr; c-erbB-1) and c-erbB-2 proteins was studied in 82 patients with primary transitional cell carcinoma of the bladder using an immuno-histochemical method. Strong or moderate staining was found in 18% of tumours for p53 with weaker staining in a further 36% giving a total of 54% of tumours stained for p53. Strong staining was found in 15% of tumours for c-erbB-2 and in 31% for the EGFr. Tumours invading the bladder muscle were significantly more likely to be strongly stained positively for p53 and/or EGFr compared with superficial tumours: only 15% of invasive tumours were stained negatively for both p53 and EGFr. No statistical association was found between p53 and EGFr expression. Weakly positive associations were found between the expression of c-erbB-2 and p53 and between muscle invasive tumours and increased expression of c-erbB-2. Alterations in the expression of p53, c-erbB-1 and c-erbB-2 were found frequently in human transitional cell carcinoma of the urinary bladder and may be of clinical use in defining patient sub-groups of differing prognosis.

MeSH Terms
Aged Biomarkers, Tumor/analysis Carcinoma, Transitional Cell/genetics,pathology ErbB Receptors/analysis,genetics Female Gene Expression Humans Male Mutation Neoplasm Staging Proto-Oncogene Proteins/analysis,genetics Receptor, ErbB-2 Staining and Labeling Tumor Suppressor Protein p53/analysis,genetics Urinary Bladder Neoplasms/genetics,pathology
Chemicals
Biomarkers, Tumor Proto-Oncogene Proteins Tumor Suppressor Protein p53 ErbB Receptors Receptor, ErbB-2
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Wright C
University Department of Pathology, Newcastle-upon-Tyne, UK.
Mellon K
Johnston P
Lane D P
Harris A L
Horne C H
Neal D E
References (32)
32 references, click to expand
  1. Expression of c-erbB-2 protein product in bladder cancer.
    Br J Cancer. 1990 Nov;62(5):764-5 PMID: 1978784
  2. T antigen is bound to a host protein in SV40-transformed cells.
    Nature. 1979 Mar 15;278(5701):261-3 PMID: 218111
  3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
    Science. 1989 May 12;244(4905):707-12 PMID: 2470152
  4. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
    Cancer Res. 1989 Apr 15;49(8):2087-90 PMID: 2564806
  5. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.
    J Virol. 1989 Feb;63(2):739-46 PMID: 2642977
  6. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.
    Lancet. 1987 Jun 20;1(8547):1398-402 PMID: 2884496
  7. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.
    Lancet. 1985 Feb 16;1(8425):366-8 PMID: 2857420
  8. Mutations in the p53 gene occur in diverse human tumour types.
    Nature. 1989 Dec 7;342(6250):705-8 PMID: 2531845
  9. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.
    Lancet. 1987 Jul 11;2(8550):69-72 PMID: 2885574
  10. Genetic alterations during colorectal-tumor development.
    N Engl J Med. 1988 Sep 1;319(9):525-32 PMID: 2841597
  11. Mouse p53 inhibits SV40 origin-dependent DNA replication.
    Nature. 1987 Oct 1-7;329(6138):458-60 PMID: 2821401
  12. Human p53 gene localized to short arm of chromosome 17.
    Nature. 1986 Feb 27-Mar 5;319(6056):783-4 PMID: 3005871
  13. Oligomerization of oncoprotein p53.
    J Virol. 1988 Dec;62(12):4737-44 PMID: 3054153
  14. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.
    Mol Cell Biol. 1989 Sep;9(9):3982-91 PMID: 2476668
  15. p53: a frequent target for genetic abnormalities in lung cancer.
    Science. 1989 Oct 27;246(4929):491-4 PMID: 2554494
  16. The p53 proto-oncogene can act as a suppressor of transformation.
    Cell. 1989 Jun 30;57(7):1083-93 PMID: 2525423
  17. Breast cancer and a proto-oncogene.
    BMJ. 1989 Oct 28;299(6707):1061-2 PMID: 2511965
  18. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
    Science. 1989 Apr 14;244(4901):217-21 PMID: 2649981
  19. Expression of the nuclear oncogene p53 in colon tumours.
    J Pathol. 1989 Mar;157(3):193-9 PMID: 2926561
  20. Allele loss on short arm of chromosome 17 in breast cancers.
    Lancet. 1988 Dec 17;2(8625):1384-5 PMID: 2904522
  21. Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung.
    Proc Natl Acad Sci U S A. 1987 Dec;84(24):9252-6 PMID: 2892196
  22. P53 expression in breast cancer.
    Int J Cancer. 1988 Feb 15;41(2):178-83 PMID: 3276632
  23. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.
    Nature. 1984 Dec 13-19;312(5995):649-51 PMID: 6390217
  24. p53 and DNA polymerase alpha compete for binding to SV40 T antigen.
    Nature. 1987 Oct 1-7;329(6138):456-8 PMID: 3309672
  25. The epidermal growth factor receptor and the prognosis of bladder cancer.
    Cancer. 1990 Apr 1;65(7):1619-25 PMID: 2311071
  26. Expression of epidermal growth factor receptor in breast carcinoma.
    J Clin Pathol. 1990 May;43(5):385-9 PMID: 2370306
  27. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
    Oncogene. 1990 Jun;5(6):893-9 PMID: 1694291
  28. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
    EMBO J. 1990 May;9(5):1595-602 PMID: 1691710
  29. Increased expression of mutant forms of p53 oncogene in primary lung cancer.
    Lancet. 1990 Mar 24;335(8691):675-9 PMID: 1969059
  30. Wild type human p53 is antiproliferative in SV40-transformed hamster cells.
    Oncogene. 1990 Jul;5(7):973-80 PMID: 2165234
  31. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer.
    Cancer Res. 1990 Jan 1;50(1):44-7 PMID: 2293558
  32. p53 mutations in colorectal cancer.
    Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9 PMID: 1699228
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
Published
1991-06-00
Pages
967-70
Language
English
Region
England
NLM ID
0370635
PMCID
PMC1972558
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com